Bluejay Diagnostics (NASDAQ:BJDX) Posts Earnings Results, Beats Estimates By $3,518.88 EPS

Bluejay Diagnostics (NASDAQ:BJDX) released its earnings results on Wednesday. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88, FiscalAI reports.

Bluejay Diagnostics Stock Performance

BJDX stock traded down $0.01 during midday trading on Thursday, reaching $1.04. The company’s stock had a trading volume of 121,852 shares, compared to its average volume of 2,500,662. Bluejay Diagnostics has a 1 year low of $0.83 and a 1 year high of $16.68. The firm has a market capitalization of $1.07 million, a price-to-earnings ratio of -0.09 and a beta of 0.89. The stock has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $2.23.

Insider Buying and Selling

In related news, major shareholder Financial Lp Hrt bought 64,047 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were acquired at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the purchase, the insider directly owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BJDX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.